India’s Glenmark Collaborates With Others For HIV-Related Drug
This article was originally published in PharmAsia News
Executive Summary
Glenmark Pharmaceuticals announced collaboration with other Indian drug makers to develop an HIV drug with several applications beyond the disease itself. The firm expects by 2010 to be able to file for U.S. approval of its crofelemer for treating several ailments, including diarrhea associated with HIV. The ability to file for the drug resulted from collaboration between Napo Pharmaceuticals and Salex Pharmaceuticals. Glenmark expects the drug to be worth $80 million in the HIV market. (Click here for more